Nordic to market Taiho anticancer in Europe
This article was originally published in Scrip
The privately owned Nordic Group is to exclusively commercialise and market Taiho Pharmaceutical's oral anticancer Teysuno in the EU and other selected European markets following the recent approval of the fluoropyrimidine drug.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.